Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell CarcinomaSean M. McBride, Nancy Y. Lee, Eric J. Sherman et al.|Journal of Clinical Oncology|2020Cited by 393
Molecular Biomarkers of Disease Outcomes and Mechanisms of Acquired Resistance to First-Line Osimertinib in Advanced EGFR-Mutant Lung CancersNoura J. Choudhury, Helena A. Yu, Soo‐Ryum Yang et al.|Journal of Thoracic Oncology|2022Cited by 95